Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > NASH management in PLWH
View:
Post by scarlet1967 on Feb 16, 2022 3:59pm

NASH management in PLWH

If you jump to 5th minute the speaker makes a reference to Tesamorelin...
https://www.clinicaloptions.com/diabetes/programs/2021/hiv-and-nash/podcast/podcast-3
Comment by realitycheck4u on Feb 16, 2022 5:37pm
This post has been removed in accordance with Community Policy
Comment by SPCEO1 on Feb 16, 2022 5:44pm
I have not had time to listen - did he say anything worthwhile?
Comment by realitycheck4u on Feb 16, 2022 6:05pm
This post has been removed in accordance with Community Policy
Comment by scarlet1967 on Feb 16, 2022 7:56pm
“Significant fibrosis” at 22% so we can rule out F1 patients which won’t need immediate care the rest F2, F3, F4 account for 22% of 1.2 millions let’s guesstimate 1/3 of 22% are F4 patients(which probably need a liver transplant rather than treatment) so about 14% and let’s say not the whole 1.2 millions were included in the statistics only 65% who are currently receiving medical care about 780000 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities